LY2940680 100mg 100mg | Purity Not Available
Adooq Bioscience
LY2940680 has been shown to affect a cancer cell signaling pathway initiated by the Hedgehog (Hh) protein.
More Information Supplier PageLY2940680 has been shown to affect a cancer cell signaling pathway initiated by the Hedgehog (Hh) protein.
More Information Supplier PageLY2940680 has been shown to affect a cancer cell signaling pathway initiated by the Hedgehog (Hh) protein.
More Information Supplier PagePHA-848125 (Milciclib) is an orally bioavailable inhibitor of CDKs and TRKA with potential antineoplastic activity.
More Information Supplier PagePHA-848125 (Milciclib) is an orally bioavailable inhibitor of CDKs and TRKA with potential antineoplastic activity.
More Information Supplier PagePHA-848125 (Milciclib) is an orally bioavailable inhibitor of CDKs and TRKA with potential antineoplastic activity.
More Information Supplier PagePHA-848125 (Milciclib) is an orally bioavailable inhibitor of CDKs and TRKA with potential antineoplastic activity.
More Information Supplier PagePHA-848125 (Milciclib) is an orally bioavailable inhibitor of CDKs and TRKA with potential antineoplastic activity.
More Information Supplier PageINCB018424 is a potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively;
More Information Supplier PageINCB018424 is a potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively;
More Information Supplier PageINCB018424 is a potent and selective inhibitor of Janus-associated kinase (JAK) 1 and 2, with IC50 to be 2.7, 4.5 and 332 nM for JAK1, JAK2 and JAK3 respectively;
More Information Supplier Page